US Patent 8,729,057: Scope, Claims, Expiration, Orange Book and Generic-Entry Risk

US Patent 8,729,057 protects a narrow testosterone hydroalcoholic gel formulation associated with the AndroGel 1.62% product profile. Its core combination is 1.3% to 1.7% testosterone, 0.9% to 1.0% isopropyl myristate, 67.0% to 74.0% lower alcohol, 0.6% to 1.4% neutralized anionic polymer, and water. The strongest practical coverage is directed to ethanol, carbomer, sodium hydroxide, and a 2.5-gram dose delivering 40.5 milligrams of testosterone.

The patent does not broadly cover all testosterone gels. A competing product that omits isopropyl myristate, uses a non-anionic gelling system, falls outside the stated concentration ranges, or uses a substantially different formulation may avoid literal infringement, subject to claim-construction and equivalents issues.

What does US Patent 8,729,057 protect?

The patent protects a composition defined by a cumulative set of formulation limitations. Each required element must be present for literal infringement of independent claim 1.

Required element	Claim 1 limitation	Practical significance
Testosterone	1.3% to 1.7% w/w	Captures formulations centered around approximately 1.5% to 1.62% testosterone
Isopropyl myristate	0.9% to 1.0% w/w	Narrow excipient limitation and important design-around point
Lower alcohol	67.0% to 74.0% w/w	Includes ethanol and specified aliphatic alcohols
Gelling agent	0.6% to 1.4% w/w	Must be an anionic polymer
Neutralization	Sufficient neutralizer to form a gel	Requires a neutralized polymeric gel system
Water	Present	Required by the claim
Dosage form	Gel pharmaceutical composition	Excludes non-gel delivery systems under ordinary claim interpretation

The claim uses “consisting of,” which generally limits the claimed composition to the listed components, although unavoidable impurities, residual processing materials, and claim-construction principles can affect the analysis. The wording creates greater design-around value than an “comprising” claim would provide.

How narrow are the testosterone concentration limits?

The independent claim covers testosterone from 1.3% through 1.7% by weight. Claim 9 narrows that range to 1.50% through 1.70%.

The commercially relevant concentration is approximately 1.62%. A formulation at 1.62% testosterone falls within both claim 1 and claim 9, assuming the other limitations are met.

A formulation at 1.29% or 1.71% testosterone is outside the literal testosterone range. That difference alone may not eliminate all infringement risk if a court applies the doctrine of equivalents, but concentration changes near a numerical claim boundary generally require a fact-intensive analysis.

The claims do not cover testosterone administered by every route. They are composition claims directed to a topical gel. Injectable testosterone esters, oral testosterone formulations, buccal systems, nasal products, patches, and implants are outside the literal scope of these claims.

What formulations are protected by claims 2 through 12?

Claims 2 through 12 progressively narrow the formulation.

Claim	Added limitation
2	The lower alcohol is ethanol
3	The ethanol is absolute ethanol
4	The ethanol is 95% v/v ethanol
5	The anionic polymer is polyacrylic acid
6	The anionic polymer is a carbomer
7	The neutralizer is selected from a specified list
8	The neutralizer is sodium hydroxide
9	Testosterone is 1.50% to 1.70% w/w
10	Absolute ethanol, carbomer neutralized with sodium hydroxide
11	Absolute ethanol, carbomer, sodium hydroxide and water
12	Sodium hydroxide is 1.0% to 10% w/w of 0.1 N sodium hydroxide

Claim 10 is the principal product-specific formulation claim. It combines the commercially important features:

1.3% to 1.7% testosterone;
0.9% to 1.0% isopropyl myristate;
67.0% to 74.0% absolute ethanol;
0.6% to 1.4% carbomer;
sodium hydroxide sufficient to form a gel; and
water.

Claim 11 is similar but separates sodium hydroxide from the gelling-agent limitation. Claim 12 adds a quantitative limitation for the sodium hydroxide solution.

A product using ethanol but not absolute ethanol may fall within claim 2 while avoiding claims 3, 10 and 11, depending on the actual alcohol composition. A product using carbomer but a neutralizer not listed in claim 7 may still infringe claims 1 or 6 if the remaining elements are present.

Does claim 14 cover the AndroGel 1.62% dose?

Yes. Claim 13 requires a therapeutically effective 2.5-gram dose for treatment of hypogonadism in a human male subject. Claim 14 narrows that dose to 40.5 milligrams of testosterone.

The calculation is:

Parameter	Amount
Gel dose	2.5 grams
Testosterone concentration	1.62% w/w
Testosterone delivered	40.5 milligrams

The 40.5-milligram limitation is consistent with the labeled starting dose for AndroGel 1.62%, although the label and patent claim serve different legal functions. A product may meet the composition limitations without being labeled for a 2.5-gram dose. Conversely, a product labeled for 2.5 grams may still avoid infringement if its formulation does not satisfy claim 1.

Claims 13 and 14 are weaker from a product-clearance perspective than the core composition claims if they are interpreted as requiring a particular therapeutic use or labeled dose. Claims 1, 10 and 11 are more important because they directly target the formulation.

When does US Patent 8,729,057 lose exclusivity?

The patent’s enforceable term depends on its earliest effective nonprovisional or international filing date, any patent-term adjustment, terminal disclaimer, and any applicable regulatory extension. The issue date, May 20, 2014, does not determine the expiration date.

The patent is part of the AndroGel 1.62% patent landscape and is commonly treated as a late-2020s formulation patent. The effective expiration date should be taken from the current USPTO patent record and FDA Orange Book listing rather than calculated solely from the grant date. Patent-term calculations can differ from the ordinary 20-year rule because of continuation practice, terminal disclaimers and patent-term adjustment.[1][2]

Patent-term analysis

Issue	Relevance to US 8,729,057
Patent type	Utility patent
Issue date	May 20, 2014
Ordinary statutory rule	Generally 20 years from the earliest effective nonprovisional filing date
Patent-term adjustment	May extend the ordinary term
Terminal disclaimer	May limit the term if filed during prosecution
Regulatory extension	Requires a specific statutory eligibility analysis
Orange Book date	Controls listed-product exclusivity analysis, not necessarily every legal-term question

The patent should be analyzed together with earlier AndroGel patents and later continuation or formulation patents. A generic applicant would typically assess the entire listed patent set, not only US 8,729,057.

What is the Orange Book status of US 8,729,057?

US 8,729,057 has been associated with the patent estate for testosterone gel products, including the AndroGel 1.62% product family. Orange Book status depends on the specific active ingredient, dosage form, strength and product listing. FDA patent listings can differ between AndroGel 1% and AndroGel 1.62%.

The relevant regulatory pathway is an abbreviated new drug application, not a biosimilar application. Testosterone is a small-molecule active pharmaceutical ingredient. FDA approval of a generic topical gel would normally require an ANDA demonstrating pharmaceutical equivalence and bioequivalence or applicable product-specific equivalence under FDA requirements.[3]

Regulatory question	Analysis
Reference product	AndroGel 1.62% topical gel is the relevant commercial comparator
FDA pathway	ANDA
Biosimilar pathway	Not applicable
Patent certification	Paragraph I, II, III or IV, depending on listed patent status
Relevant patents	Formulation, composition, method-of-use and potentially manufacturing patents
Regulatory exclusivity	Separate from patent term and must be evaluated independently

Orange Book listing does not establish that every claim is valid or infringed. It creates the statutory framework for patent certification and, after a Paragraph IV notice, potential Hatch-Waxman litigation.

Which companies have challenged the AndroGel 1.62% patent estate?

Generic manufacturers have pursued testosterone gel products through the ANDA pathway, creating Paragraph IV and settlement risk around the AndroGel patent portfolio. Publicly reported challengers and generic participants have included major companies such as Teva, Actavis, Perrigo and related commercial entities, depending on the specific product and period.

The relevant legal question is not whether a company challenged US 8,729,057 in isolation. ANDA applicants commonly challenge multiple Orange Book-listed patents in a single certification strategy. Litigation may involve:

invalidity;
non-infringement;
unenforceability;
written description;
enablement;
obviousness;
indefiniteness;
patent listing disputes; and
settlement-related launch rights.

A Paragraph IV certification does not itself invalidate the patent or authorize immediate commercial launch. If the NDA holder or patent owner files suit within the statutory period, FDA approval can be subject to a 30-month stay, subject to statutory exceptions and court developments.[4]

What patent litigation affects US 8,729,057?

The core litigation risk is Hatch-Waxman litigation against an ANDA applicant seeking approval for a testosterone gel matching the reference product. The asserted patent portfolio may include multiple patents covering different aspects of AndroGel 1.62%, including:

Patent category	Typical protected subject matter
Composition patents	Testosterone concentration, alcohol, penetration enhancer, polymer and water
Formulation patents	Gel rheology, excipient ratios and neutralization
Method-of-use patents	Treatment of male hypogonadism or testosterone deficiency
Delivery patents	Dose volume, pump operation and administration regimen
Manufacturing patents	Mixing, dissolution, neutralization and filling processes

A defendant has a stronger non-infringement position if its formulation changes several claim-critical variables at once. Changing only the testosterone concentration while retaining the same excipient architecture may create a narrower but still material dispute.

The strongest invalidity issues would likely focus on obviousness and written description. The claim combines known formulation components, but the patent owner may rely on the claimed concentration windows, gel performance, testosterone delivery and product stability to defend non-obviousness. Written-description analysis would examine whether the specification supports the full numerical ranges and every listed alcohol, polymer and neutralizer.

How strong is the patent estate for generic-entry purposes?

US 8,729,057 has moderate-to-strong blocking value against a close copy of the claimed formulation. Its strength is highest when a proposed generic uses:

approximately 1.62% testosterone;
approximately 0.95% isopropyl myristate;
approximately 70% ethanol;
carbomer;
sodium hydroxide; and
a 2.5-gram application delivering 40.5 milligrams.

Its strength declines when a competitor changes multiple formulation variables. The isopropyl myristate range is particularly narrow. A formulation with no isopropyl myristate, or with a materially different penetration enhancer, may present a substantial design-around route.

Principal vulnerability points

The independent claim requires a narrow isopropyl myristate range.
“Consisting of” may restrict additional excipients.
A competitor can target a non-anionic gelling system.
The 2.5-gram and 40.5-milligram limitations may not apply to all product presentations.
Earlier patents may limit the practical value of arguing that the claimed combination is novel solely because it contains testosterone, ethanol and carbomer.
Generic approval may proceed with a formulation that is therapeutically substitutable but not compositionally identical.

What generic launch scenarios exist?

Scenario 1: Full formulation match

A generic reproduces the concentration and excipient profile. This creates the highest direct infringement exposure under claims 1, 6, 8, 9, 10 and 11, with claim 14 potentially relevant to a 2.5-gram dose.

Scenario 2: Formulation design-around

A generic changes isopropyl myristate, the gelling polymer, the neutralizer or alcohol concentration. This can reduce literal infringement risk but may trigger regulatory comparability and bioequivalence challenges.

Scenario 3: Carve-out or label strategy

A generic may seek approval with a permitted labeling strategy that excludes patented methods of use. This approach does not avoid composition claims. It is more relevant to method-of-use patents than to claims 1, 10 and 11.

Scenario 4: Authorized generic

The patent holder or NDA holder may license or authorize a generic launch under a settlement or commercial agreement. The launch date then depends on contractual terms rather than only patent expiration.

Are there biosimilar risks?

No biosimilar pathway applies to testosterone gel. Testosterone is a chemically defined small molecule. Competitive risk comes from ANDA applicants, authorized generics, private-label products and potentially alternative testosterone delivery systems.

The commercial threat is therefore a conventional generic erosion event. The timing depends on patent certifications, litigation, settlements, FDA approval and any agreed launch date.

How does US 8,729,057 compare with other testosterone patents?

Patent estate	Primary risk
Earlier AndroGel patents	Foundational composition or use coverage; some may have expired or become less commercially important
US 8,729,057	Narrow formulation coverage centered on testosterone, isopropyl myristate, ethanol, carbomer and sodium hydroxide
Later formulation patents	Potentially extend protection for concentration, dosing, pump delivery, stability or administration
Method-of-use patents	May affect label strategy but do not necessarily block a non-infringing formulation
Alternative testosterone products	Create substitution risk without directly infringing this gel composition

The patent should not be treated as the entire AndroGel 1.62% estate. Freedom-to-operate analysis must include all unexpired patents listed for the reference product, relevant continuations and non-Orange-Book patents covering manufacturing or commercial presentation.

What geographic coverage does the patent provide?

US 8,729,057 provides protection only in the United States. Foreign family members, if granted, must be analyzed separately in each jurisdiction. Claim scope, term, prosecution history, patent-linkage rules and generic litigation procedures vary across Europe, Canada, Japan, Australia and other markets.

A US design-around does not establish freedom to operate abroad. Conversely, a formulation infringing a foreign counterpart may not infringe the US patent if the foreign claims differ.

Key Takeaways

US 8,729,057 is a formulation patent, not a broad patent on testosterone therapy.
Claim 1 requires testosterone, isopropyl myristate, lower alcohol, neutralized anionic polymer and water within specified ranges.
Claims 10 and 11 most closely target an AndroGel 1.62%-type formulation.
Claim 14 captures a 2.5-gram dose containing 40.5 milligrams of testosterone.
The narrow 0.9% to 1.0% isopropyl myristate range is a significant design-around opportunity.
A non-anionic gelling system, different penetration enhancer or materially different alcohol concentration may avoid literal infringement.
Testosterone products compete through ANDAs, not biosimilar applications.
Paragraph IV litigation must be evaluated across the full Orange Book patent estate, not US 8,729,057 alone.
Patent expiration must be confirmed from the USPTO term record and current Orange Book listing.
The commercial outcome depends on patent term, settlements, authorized-generic arrangements, FDA approval and formulation design.

FAQs About US Patent 8,729,057

Does a 1.62% testosterone gel automatically infringe US 8,729,057?

No. The product must also satisfy the isopropyl myristate, alcohol, anionic polymer, neutralization and water limitations, along with any relevant dependent-claim requirements.

Can a testosterone gel avoid the patent by using 2.0% testosterone?

A 2.0% formulation is outside the express 1.3% to 1.7% testosterone range. Other patents and the doctrine of equivalents still require separate analysis.

Does removing isopropyl myristate avoid the patent?

It generally avoids literal infringement of claim 1 because isopropyl myristate is a required element. Other patents, including formulation or manufacturing patents, may remain relevant.

Does a generic need to copy the 2.5-gram dose?

No. The 2.5-gram and 40.5-milligram limitations appear in dependent claims 13 and 14. Claims 1 through 12 do not require that specific dose.

Is US 8,729,057 a patent on AndroGel itself?

It is part of the patent landscape associated with testosterone gel products, including the AndroGel 1.62% formulation profile. It does not cover every testosterone gel or every AndroGel presentation.

What is the principal invalidity argument against the patent?

The principal candidates are obviousness and written description, particularly whether the claimed concentration ranges and excipient combination would have been predictable from earlier testosterone gel formulations and whether the specification adequately supports the full claim scope.

Sources

United States Patent and Trademark Office. (2014). U.S. Patent No. 8,729,057.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation resources.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and patent certification requirements.
U.S. Food and Drug Administration. (2023). AndroGel 1.62% testosterone gel prescribing information.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Besins Hlthcare	ANDROGEL	testosterone	GEL, METERED;TRANSDERMAL	022309-001	Apr 29, 2011	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Besins Hlthcare	ANDROGEL	testosterone	GEL;TRANSDERMAL	022309-002	Sep 7, 2012	AB2	RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Besins Hlthcare	ANDROGEL	testosterone	GEL;TRANSDERMAL	022309-003	Sep 7, 2012	AB2	RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006299833	⤷ Start Trial
Brazil	PI0617294	⤷ Start Trial
Canada	2624788	⤷ Start Trial
China	101287470	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,729,057

Which drugs does patent 8,729,057 protect, and when does it expire?

Summary for Patent: 8,729,057